Avanos Medical, INC. (FKA Halyard Health, INC.)

Medical device manufacturer.

Based in GA

Share:𝕏LinkedInFacebook
🤖

AI Overview

With $1.2M in lobbying spend across 21 quarterly filings, Avanos Medical, INC. (FKA Halyard Health, INC.) is a significant lobbying presence. Their lobbying covers 3 issue areas. Active from 2018 to 2025.

$1.2M
Total Spend
7
Years Active
1
Firms Hired
6
Lobbyists Deployed
3
Issues Lobbied

Spending Trend

View as table
YearLobbying Spend
2018$120K
2019$180K
2020$240K
2021$240K
2022$30K
2024$180K
2025$240K

Issues Lobbied

Health IssuesMedicare/MedicaidTrade

Lobbying Firms

Polsinelli PC

Lobbyists

Michael GabaSteven StranneTim PerrinRobert DaleyTimothy CaseyShelagh Foster

What They Lobby About

These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues, Medicare/Medicaid, Trade

Help in the reduction of opioid use and related addiction.

Legislation related to the reduction of opioid use and related addictions.

HR 5776 Medicare and Opioid Safe Treatment Act

HR 6 21st Century Cures Act (Substance Use and Disorder Prevention that Promotes Opioid Recovery and Treatment)

Legislation related to the reduction of opioid use and related addictions

HR 5776 Medicare and Opioid Safe Treatment Act

HR 6 Support for Patients and Communities Act

* Legislation related to the reduction of opioid use and related addictions

* Implementation of HR 6, SUPPORT for Patients and Communities Act

* Medical Device Tax Repeal Legislation

* Legislation related to the reduction of opioid use and related addictions

* Implementation of HR 6, SUPPORT for Patients and Communities Act

* Medical Device Tax Repeal Legislation

* S 692/HR 2207 Protect Medical Innovation Act of 2019

* Legislation related to the reduction of opioid use and related addictions

* Implementation of HR 6, SUPPORT for Patients and Communities Act

* Medical Device Tax Repeal Legislation

* S 692/HR 2207 Protect Medical Innovation Act of 2019

S 3067/HR 5172 Non-Opioid Prevention Addiction in the Nation Act

* Legislation related to the reduction of opioid use and related addictions

* Implementation of HR 6, SUPPORT for Patients and Communities Act

S 3067/HR 5172 Non-Opioid Prevention Addiction in the Nation Act

Legislation related to the reduction of opioid use and related addictions

S.586-NOPAIN Act

S. 987-Comprehensive Addiction and Recovery Act (CARA) 3.0

Showing 8 of 16 unique descriptions from filings.

Related Analysis

📈 Client Trajectories
See how this client compares to others over time
🎯 Market Concentration
How concentrated is the lobbying market?
🚀 Spending Momentum
Which issues are surging right now?
🏭 Pharma Lobbying
Industry overview and top spenders

Related Investigations

Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Healthcare's $3 Billion Bet
The healthcare industry's massive lobbying investment.
The 2025 Tariff Panic
As tariffs return, lobbying on trade surges.
Federal Lobbying Statistics 2025
The definitive stats — $15.2B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.

Explore More

← All Clients⚖️ Compare Clients💵 ROI Calculator🔍 Investigations📖 How Lobbying Works🕸️ Network Analysis

Data Sources: Senate LDA Filings

Last updated: February 2026

This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.